Kalina Scott appointed new CFO of Polyphor

Kalina Scott will join Polyphor as Chief Financial Officer as of June 1st, 2017. She brings over 20 years of experience in the fields of mergers & acquisitions, capital markets and private placements in particular in the healthcare field, most recently as Managing Director, Corporate Finance with Bank am Bellevue in Zurich.

Kalina started her career at UBS focusing on structured finance and credit risk management, followed by leading roles in UBS's investment banking in Zurich and London, covering leveraged finance as well as mergers & acquisitions, and in KPMG's Corporate Finance, where she built an IPO advisory unit. During her career, she successfully executed corporate finance transactions for more than 20 companies companies - including the IPOs of Molecular Partners, Cassiopea and more recently Galenica Santé, as well as strategic transactions for Berna Biotech, Sulzer Medica, Mathys Medical and the Hirslanden group. Kalina succeeds Alain Schaffter, who will leave Polyphor to take on a new challenge.

Giacomo Di Nepi, Polyphor's CEO, commented: "I am very pleased that Kalina has decided to join Polyphor. Her extensive experience in the finance area, combined with her transaction-based expertise in healthcare and her broad network will help to grow Polyphor and support our corporate strategy and transformation. I would also like to thank Alain for his contribution and wish him all the best in his new endeavors".

"I am honored and very excited about the opportunity to support Polyphor in its goal to become the leader in the development of powerful therapies that help patients to improve their lives and, through this and its corporate development, to bring value to the shareholders", says Kalina Scott.

Kalina Scott, a Swiss and Bulgarian citizen, studied Business and Economics at the University of Leipzig, Germany, and is a Bachelor of Business Administration of the Sofia University in Bulgaria.